Literature DB >> 6181537

Effects of chronic administration of somatostatin on rat exocrine pancreas.

J Morisset, P Génik, A Lord, T E Solomon.   

Abstract

We studied the effects of somatostatin on synthesis of pancreatic DNA, RNA and protein and on pancreatic weight and contents of DNA, protein, amylase and chymotrypsinogen in rats. In short term synthesis studies, rats were injected with 100 micrograms . kg-1 somatostatin or 0.15 M NaCl (control) at times 0, 8 and 16 h. Eight rats from each treatment group were killed 2, 4, 8, 12, 16, 20 and 24 h after beginning treatment. Incorporation rates in vivo of [3H]thymidine into DNA, [3H]uridine into RNA and [14C]phenylalanine into total protein were significantly depressed by somatostatin. In long term studies, four groups of 12 rats were injected every 8 h for 5 days with 0.15 M NaCl or 11, 33 or 100 micrograms . kg-1 somatostatin. Body weight was unaffected but pancreatic contents of DNA, protein and enzymes were significantly decreased by somatostatin. Administration of somatostatin inhibits DNA, RNA and protein synthesis in exocrine pancreas with resulting decreases in DNA and enzyme contents.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181537     DOI: 10.1016/0167-0115(82)90108-2

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  9 in total

Review 1.  Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine.

Authors:  L Rosenberg
Journal:  Int J Pancreatol       Date:  1997-10

2.  Effect of somatostatin on the growth of gastrointestinal mucosa and pancreas in rats. Role of endogenous gastrin.

Authors:  A Dembiński; Z Warzecha; S J Konturek; A V Schally
Journal:  Gut       Date:  1987       Impact factor: 23.059

Review 3.  Pancreatic cancer: a review of emerging therapies.

Authors:  L Rosenberg
Journal:  Drugs       Date:  2000-05       Impact factor: 9.546

4.  Time course and cellular site of mitotic activity in the exocrine pancreas of the rat during sustained hormone stimulation.

Authors:  H Lütcke; G A Scheele; H F Kern
Journal:  Cell Tissue Res       Date:  1987-02       Impact factor: 5.249

5.  Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses.

Authors:  S M Wood; M E Kraenzlin; T E Adrian; S R Bloom
Journal:  Gut       Date:  1985-05       Impact factor: 23.059

6.  Enteroendocrine cells in the developing opossum small intestine and colon.

Authors:  W J Krause; J Yamada; J H Cutts
Journal:  J Anat       Date:  1989-02       Impact factor: 2.610

Review 7.  Gastrointestinal hormones as potential adjuvant treatment of exocrine pancreatic adenocarcinoma.

Authors:  W E Fisher; P Muscarella; L G Boros; W J Schirmer
Journal:  Int J Pancreatol       Date:  1998-12

Review 8.  Biology of pancreatic cancer.

Authors:  G J Poston; J Gillespie; P J Guillou
Journal:  Gut       Date:  1991-07       Impact factor: 23.059

9.  Effect of diabetes mellitus on pancreatic exocrine secretion from isolated perfused pancreas in rats.

Authors:  Y Okabayashi; M Otsuki; A Ohki; I Suehiro; S Baba
Journal:  Dig Dis Sci       Date:  1988-06       Impact factor: 3.199

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.